NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...

Morgan Stanley lowered shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) from an overweight rating to an equal ...

Morgan Stanley has recently reduced Intellia Therapeutics Inc (NTLA) stock rating, as announced on January 27, 2025, according to Finviz. Earlier, on February 23, 2024, Goldman had reduced the stock ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization. Read more about EDIT and NTLA stocks here.

The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.

Intellia Therapeutics Inc (NTLA) stock saw a decline, ending the day at $10.99 which represents a decrease of $-0.30 or -2.66% from the prior close of $11.29. The stock opened at $11.25 and touched a ...

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price target dropped by equities research analysts at BMO Capital Markets from $70.00 to $50.00 in a research report issued to clients and ...

Morgan Stanley (NYSE:MS) adjusted its stance on Intellia Therapeutics shares, downgrading the biotechnology company from Overweight to Equalweight. Accompanying this change, the firm also ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

It has been many moons since I last held a position in Intellia Therapeutics, Inc. (NASDAQ:NTLA). At that time, cutting-edge biotech companies going after CAR-T therapies and gene therapies were ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...